Book Value per Share: Maze Tx (MAZE)

Graphic logo of Maze Therapeutics Inc (MAZE)

The price trend shown below illustrates the dynamics of Maze Therapeutics Inc (MAZE), whose strategy relies on AI-driven mutation analysis and rigorous patent protection. The current figure is 8.19. The team retains leading genomics experts through a stock option system, despite the industry's talent shortage. Expansion flexibility is ensured by outsourcing manufacturing and clinical trials to third-party contractors.

Maze Tx (MAZE) Equity per Share: for the period 02/01/2025 - 10/28/2026
Manufactured products of Maze Therapeutics

The foundation of Maze Therapeutics Inc (MAZE) resilience lies in its ownership of exclusive patents in the field of genetic editing. The book value per share, which stands at 8.19, reflects the company's net asset value attributable to a single share. Investors utilize this ratio to assess the real protection of capital against volatility. An increase in this metric confirms the effective accumulation of intellectual and cash assets. By analyzing the book value per share trend, one can determine whether the asset is overvalued relative to its tangible base.

Competitor analysis

Accounting Value per Share Tempus AI, Inc.|QGEN - Share Book Value|Book Value per Share IONS|repligen.com (RGEN) - Net Asset Value per Share|Book Value per Share Avidity Biosciences, Inc. (RNA)|Equity per Share CRSP|Net Assets per Single Share Sema4 WGS|Equity per Share Ultragenyx Corp (RARE)|Book Value per Share BEAM (Beam Therapeutics Inc.)|sarepta.com - Book Value per Share|TWST: Net Assets per Single Share|TXG - Accounting Value per Share|NTLA: Book Value per Share|Book Value per Share Stoke Corp|Accounting Value per Share BioLife Solutions, Inc. BLFS|Share Book Value wavelifesciences.com|Sionna Therapeutics - Book Value per Share|Net Asset Value per Share Prime Medicine Inc PRME|Accounting Value per Share Taysha|QURE - Accounting Value of a Share|Accounting Value per Share MeiraGTx Holdings plc MGTX|RGNX - Book Price of a Share|Book Value per Share Solid Biosciences SLDB|Ocugen Inc (OCGN) - Accounting Value of a Share|Book Value per Share PACB (Pacific Biosciences of California)|Net Asset Value per Share BNTC|Design Therapeutics (DSGN) - Net Assets per Single Share|Accounting Value of a Share rocketpharma.com (RCKT)|Book Value per Share FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics Inc. - Book Value per Share|Net Assets per Single Share Korro Bio, Inc|EDIT - Share Book Value|Book Value per Share SLN|Net Asset Value per Share ProQR Therapeutics|CDXS (Codexis Inc) - Accounting Value per Share|Book Value per Share Sangamo Therapeutics Inc. (SGMO)|Accounting Value per Share Nautilus Biotechnology|Book Price of a Share Metagenomi Therapeutics (MGX)|Book Value per Share DTIL|Net Assets per Share Generation Bio Co GBIO|BOLD: Book Value per Share|XCUR: Accounting Value per Share|imunon.com - Net Assets per Single Share|Net Assets per Share Phio Pharmaceuticals Corp.|MBIO - Accounting Value per Share|Accounting Value of a Share TransCode|BNGO (Bionano Genomics, Inc.) - Book Value per Share|Net Assets per Share APDN (Applied DNA Sciences Inc)|BLUE - Net Assets per Single Share|Equity per Share ImmunoPrecise Antibodies Ltd IPA|OMGA: Book Value per Share|OMIC: Accounting Value per Share|RGLS (Regulus Therapeutics Inc.) - Net Assets per Single Share|Syros Pharmaceuticals Inc. (SYRS) - Accounting Value per Share|TBIO (Codex DNA) - Book Value per Share|Book Value per Share TRACON Pharmaceuticals, Inc (TCON)|UBX - Accounting Value per Share